{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:03:49Z","timestamp":1768010629044,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SPUM 33CM30-124112"],"award-info":[{"award-number":["SPUM 33CM30-124112"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SPUM 33CM30-140 336"],"award-info":[{"award-number":["SPUM 33CM30-140 336"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SNSF 32473B_163271"],"award-info":[{"award-number":["SNSF 32473B_163271"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006388","name":"Geneva University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eugenio Litta Foundation"},{"name":"Arthemis Foundation"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SNSF 320030-172676"],"award-info":[{"award-number":["SNSF 320030-172676"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004362","name":"Swiss Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ijcard.2019.12.011","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T16:45:33Z","timestamp":1575996333000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort"],"prefix":"10.1016","volume":"303","author":[{"given":"Baris","family":"Gencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nanchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos C.","family":"Koskinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Klingenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reto","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dik","family":"Heg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Felix","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Matter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Rodondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.12.011_bb0005","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1093\/eurheartj\/ehy554","article-title":"Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014","volume":"39","author":"Szummer","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2019.12.011_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0020","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials","volume":"39","author":"Koskinas","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0025","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0030","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0035","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"2018","author":"Grundy","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0040","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"2019","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006537","article-title":"Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology\/European Atherosclerosis Society (ESC\/EAS) guidelines after acute coronary syndromes","volume":"6","author":"Gencer","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0050","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","article-title":"Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes","volume":"36","author":"Nanchen","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0055","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.116.023007","article-title":"Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes","volume":"134","author":"Nanchen","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.atherosclerosis.2014.12.049","article-title":"Expected impact of applying new 2013 AHA\/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes","volume":"239","author":"Gencer","year":"2015","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093147","article-title":"Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications","volume":"9","author":"Auer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2019.12.011_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2014.12.014","article-title":"Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes","volume":"26","author":"Gencer","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0080","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0085","first-page":"129","article-title":"Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score","volume":"7","author":"Klingenberg","year":"2018","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"10.1016\/j.ijcard.2019.12.011_bb0090","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1093\/eurheartj\/ehx640","article-title":"Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes","volume":"38","author":"Klingenberg","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0095","first-page":"814","article-title":"Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors","volume":"38","author":"Li","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0100","doi-asserted-by":"crossref","first-page":"g1407","DOI":"10.1136\/bmj.g1407","article-title":"Relative risks versus odds ratios","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0105","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0110","first-page":"2245","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2018.01.012","article-title":"Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies","volume":"269","author":"Gragnano","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ehjcvp\/pvx010","article-title":"Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting","volume":"4","author":"Korman","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"9","key":"10.1016\/j.ijcard.2019.12.011_bb0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamacardio.2019.2306","article-title":"Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial","volume":"4","author":"Bach","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0130","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Writing","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0140","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0145","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0150","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","article-title":"PCSK9 inhibitors: economics and policy","volume":"70","author":"Hlatky","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0155","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamainternmed.2017.0754","article-title":"Applicability of the IMPROVE-IT trial to current patients with acute coronary syndrome: an NCDR research to practice project","volume":"177","author":"Maddox","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcard.2019.12.011_bb0165","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319347928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319347928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:46:04Z","timestamp":1759092364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527319347928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"alternative-id":["S0167527319347928"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.12.011","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}